Top

Published in:

01-12-2013 | Biomarkers of Heart Failure (WHW Tang, Section Editor)

The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers

Authors: George Karayannis, Filippos Triposkiadis, John Skoularigis, Panagiotis Georgoulias, Javed Butler, Gregory Giamouzis

Published in: Current Heart Failure Reports | Issue 4/2013

Abstract

Heart failure (HF) is a leading cause of morbidity and mortality worldwide and, despite recent advances in therapy HF hospitalization rates remains unacceptably high. Prompt identification and optimal management of HF can affect long-term outcome. A valuable tool with diagnostic, prognostic, and treatment-guiding properties in this respect will be very useful, as exemplified by natriuretic peptides. However, natriuretic peptide levels show biological variation and are dependent on age, renal function, and body mass index. Recent advances in the field of molecular biology and HF pathophysiology have led to the discovery of other novel biomarkers that may have advantages. Among others, Galectin-3 (GAL3) and sST2 are 2 promising biomarkers that have been recently developed and can be used alone or in combination with natriuretic peptides in clinical practice. In the current paper, we review the existing data regarding GAL3 and sST2 in HF.

Sherwi N, Merali S, Wong K. Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol. 2012;8(6):885–94. doi:10.2217/fca.12.65.PubMedCrossRef

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6. doi:10.1161/CIRCULATIONAHA.108.191259.PubMedCrossRef

Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL, Dunbar S, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Cardiac Failure. 2011;17(1):54–75. doi:10.1016/j.cardfail.2010.08.010.CrossRef

Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013;165(6):995–9. doi:10.1016/j.ahj.2013.02.029.PubMedCrossRef

Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52(18):1458–65. doi:10.1016/j.jacc.2008.07.042.PubMedCrossRef

de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Failure Rep. 2010;7(1):1–8. doi:10.1007/s11897-010-0004-x.CrossRef

Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991;266(28):18731–6.PubMed

Sato S, Hughes RC. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem. 1992;267(10):6983–90.PubMed

Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007;31(7):655–62. doi:10.1016/j.cellbi.2006.11.036.PubMedCrossRef

10.

Hattasch R, Spethmann S, de Boer RA, Ruifrok WP, Schattke S, Wagner M, et al. Galectin-3 increase in endurance athletes. Eur J Prev Cardiol. 2013. doi:10.1177/2047487313492069.PubMed

11.

• Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8. doi:10.1161/01.CIR.0000147181.65298.4D. Experimental evidence of adverse pathophysiological effects of galectin-3 on the heart.PubMedCrossRef

12.

Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol. 2008;75(9):1797–806. doi:10.1016/j.bcp.2008.02.003.PubMedCrossRef

13.

•• Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296(2):H404–12. doi:10.1152/ajpheart.00747.2008. This article supports the feasibility of anti-galectin therapy by demonstrating that it can prevent maldaptive remodelling.PubMedCrossRef

14.

Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747–62. doi:10.1016/j.jacc.2009.05.015.PubMedCrossRef

15.

Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103(13):5060–5. doi:10.1073/pnas.0511167103.PubMedCrossRef

16.

Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int: Off J Jpn Soc Allergol. 2007;56(1):57–65. doi:10.2332/allergolint.O-06-449.CrossRef

17.

Wang L, Friess H, Zhu Z, Frigeri L, Zimmermann A, Korc M, et al. Galectin-1 and galectin-3 in chronic pancreatitis. Laboratory investigation. J Tech Methods Pathol. 2000;80(8):1233–41.

18.

• Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta; Int J Clin Chem. 2009;409(1–2):96–9. doi:10.1016/j.cca.2009.09.001. Evidence of significant relation of galectin-3 with procollagen III N-terminal peptide.CrossRef

19.

Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens. 2004;64(1):1–12. doi:10.1111/j.0001-2815.2004.00278.x.PubMedCrossRef

20.

Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Kupper I, et al. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol. 2007;171(2):463–72. doi:10.2353/ajpath.2007.060906.PubMedCrossRef

21.

Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun. 2001;280(4):1183–8. doi:10.1006/bbrc.2001.4256.PubMedCrossRef

22.

Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol. 1998;152(5):1199–208.PubMed

23.

Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol: Off J German Cardiac Soc. 2013;102(2):103–10. doi:10.1007/s00392-012-0500-y.CrossRef

24.

Kortekaas KA, Hoogslag GE, de Boer RA, Dokter MM, Versteegh MI, Braun J, et al. Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair. Eur J Heart Failure. 2013. doi:10.1093/eurjhf/hft056.

25.

Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385–90. doi:10.1016/j.amjcard.2011.03.056.PubMedCrossRef

26.

Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers: Biochem Indic Expo, Response, Susceptibility Chem. 2012;17(8):706–13. doi:10.3109/1354750X.2012.719037.

27.

Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Failure. 2012;5(1):72–8. doi:10.1161/CIRCHEARTFAILURE.111.963637.CrossRef

28.

Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 2012;1(5):e000760. doi:10.1161/JAHA.112.000760.PubMedCrossRef

29.

Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Failure. 2013;6(3):492–8. doi:10.1161/CIRCHEARTFAILURE.112.000146.CrossRef

30.

• van Kimmenade RR, Januzzi Jr JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–24. doi:10.1016/j.jacc.2006.03.061. This article demonstrates the diagnostic capability of galectin-3 in acute heart failure patients.PubMedCrossRef

31.

Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Failure. 2010;12(8):826–32. doi:10.1093/eurjhf/hfq091.CrossRef

32.

• van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Failure. 2013;6(2):219–26. doi:10.1161/CIRCHEARTFAILURE.112.000129. This article confirms the significant prognostic value of galectin-3 in both chronic and acute decompensated heart failure patients.CrossRef

33.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Failure. 2013. doi:10.1093/eurjhf/hft075.

34.

• Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Failure. 2013;15(5):511–8. doi:10.1093/eurjhf/hfs205. A large study confirming the association of increased galectin-3 with severe HF and renal dysfunction, as well as differential effects of valsartan on outcomes in relation to galectin-3 levels.CrossRef

35.

Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol: Off J German Cardiac Soc. 2010;99(5):323–8. doi:10.1007/s00392-010-0125-y.CrossRef

36.

de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8. doi:10.3109/07853890.2010.538080.PubMedCrossRef

37.

Lok DJ, Klip IT, Lok SI, de la Bruggink-Andre de la Porte PW, Badings E, van Wijngaarden J, et al. Incremental prognostic power of novel biomarkers (Growth-Differentiation Factor-15, High-Sensitivity C-Reactive Protein, Galectin-3, and High-Sensitivity Troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013. doi:10.1016/j.amjcard.2013.05.013.PubMed

38.

Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant: Official Publ Inter Soc Heart Transplant. 2008;27(6):589–96. doi:10.1016/j.healun.2008.02.018.CrossRef

39.

Erkilet G, Ozpeker C, Bothig D, Kramer F, Rofe D, Bohms B, et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 2013;32(2):221–30. doi:10.1016/j.healun.2012.11.011.CrossRef

40.

Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60(14):1249–56. doi:10.1016/j.jacc.2012.04.053.PubMedCrossRef

41.

de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Int Med. 2012;272(1):55–64. doi:10.1111/j.1365-2796.2011.02476.x.CrossRef

42.

Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012;58(1):267–73. doi:10.1373/clinchem.2011.174359.PubMedCrossRef

43.

Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012;19(12):1073–82.PubMedCrossRef

44.

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33(18):2290–6. doi:10.1093/eurheartj/ehs077.PubMedCrossRef

45.

Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Failure. 2012;14(1):74–81. doi:10.1093/eurjhf/hfr151.CrossRef

46.

Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Failure. 2013;6(1):107–17. doi:10.1161/CIRCHEARTFAILURE.112.971168.CrossRef

47.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler, Thromb, Vascr Biol. 2013;33(1):67–75. doi:10.1161/ATVBAHA.112.300569.CrossRef

48.

Bichara M, Attmane-Elakeb A, Brown D, Essig M, Karim Z, Muffat-Joly M, et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology. 2006;16(1):36–45. doi:10.1093/glycob/cwj035.PubMedCrossRef

49.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New Eng J Med. 1999;341(10):709–17. doi:10.1056/NEJM199909023411001.PubMedCrossRef

50.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Eng J Med. 2003;348(14):1309–21. doi:10.1056/NEJMoa030207.PubMedCrossRef

51.

Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem/FEBS. 1999;264(2):397–406.CrossRef

52.

Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7(10):827–40. doi:10.1038/nrd2660.PubMedCrossRef

53.

Januzzi Jr JL. ST2 As a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013;6(4):493–500. doi:10.1007/s12265-013-9459-y.PubMedCrossRef

54.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90. doi:10.1016/j.immuni.2005.09.015.PubMedCrossRef

55.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–6.PubMedCrossRef

56.

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig. 2007;117(6):1538–49. doi:10.1172/JCI30634.PubMedCrossRef

57.

Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Failure. 2009;2(6):684–91. doi:10.1161/CIRCHEARTFAILURE.109.873240.CrossRef

58.

Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42(3):358–64. doi:10.1016/j.cyto.2008.03.008.PubMedCrossRef

59.

Fagundes CT, Amaral FA, Souza AL, Vieira AT, Xu D, Liew FY, et al. ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukoc Biol. 2007;81(2):492–9. doi:10.1189/jlb.0606422.PubMedCrossRef

60.

Abston ED, Barin JG, Cihakova D, Bucek A, Coronado MJ, Brandt JE, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Failure. 2012;5(3):366–75. doi:10.1161/CIRCHEARTFAILURE.111.963769.CrossRef

61.

Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52(25):2166–74. doi:10.1016/j.jacc.2008.09.027.PubMedCrossRef

62.

Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16–26. doi:10.1016/j.yjmcc.2013.03.020.PubMedCrossRef

63.

Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, Hantusch B, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond). 2013;37(5):658–65. doi:10.1038/ijo.2012.118.CrossRef

64.

Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012;58(12):1673–81. doi:10.1373/clinchem.2012.192153.PubMedCrossRef

65.

• Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Failure. 2009;2(4):311–9. doi:10.1161/CIRCHEARTFAILURE.108.833707. This article reveals that sST2 concentrations are associated with left ventricular structural abnormalities, decompensation and long-term in acute dyspneic patients.CrossRef

66.

Weinberg EO. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomarkers Med. 2009;3(5):495–511. doi:10.2217/bmm.09.56.CrossRef

67.

Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–50. doi:10.1016/j.jacc.2009.08.047.PubMedCrossRef

68.

Willems S, Sels JW, Flier S, Versteeg D, Buhre WF, de Kleijn DP, et al. Temporal changes of soluble ST2 after cardiovascular interventions. Eur J Clin Investig. 2013;43(2):113–20. doi:10.1111/eci.12022.CrossRef

69.

Januzzi Jr JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50(7):607–13. doi:10.1016/j.jacc.2007.05.014.PubMedCrossRef

70.

Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Cardiac Failure. 2012;18(4):304–10. doi:10.1016/j.cardfail.2012.01.008.CrossRef

71.

Dieplinger B, Januzzi Jr JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta; Int J Clin Chem. 2009;409(1–2):33–40. doi:10.1016/j.cca.2009.08.010.CrossRef

72.

Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Cardiac Failure. 2013;19(3):163–8. doi:10.1016/j.cardfail.2013.01.010.CrossRef

73.

Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol. 2008;130(4):578–84. doi:10.1309/WMG2BFRC97MKKQKP.PubMedCrossRef

74.

Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259–67. doi:10.1016/j.amjcard.2010.09.011.PubMedCrossRef

75.

• Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Failure. 2012;14(1):32–8. doi:10.1093/eurjhf/hfr156. The additive prognostic value of combined use of ST2 and NTproBNP for risk stratification for death in heart failure patients. CrossRef

76.

Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752–6. doi:10.1373/clinchem.2007.096560.PubMedCrossRef

77.

Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Failure. 2011;13(7):718–25. doi:10.1093/eurjhf/hfr047.CrossRef

78.

Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi Jr JL. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135. doi:10.1186/cc11440.PubMedCrossRef

79.

Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–6.PubMedCrossRef

80.

Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Cardiac Failure. 2008;14(9):732–8. doi:10.1016/j.cardfail.2008.06.415.CrossRef

81.

Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Failure. 2011;4(2):180–7. doi:10.1161/CIRCHEARTFAILURE.110.958223.CrossRef

82.

Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, Agha SA, Rashad MA, Laskar SR, et al. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J. 2009;157(2):299–305. doi:10.1016/j.ahj.2008.10.007.PubMedCrossRef

83.

Agha SA, Kalogeropoulos AP, Shih J, Georgiopoulou VV, Giamouzis G, Anarado P, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Cardiac Failure. 2009;15(7):586–92. doi:10.1016/j.cardfail.2009.03.002.CrossRef

84.

• Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Failure. 2012;14(3):268–77. doi:10.1093/eurjhf/hfs006. This article underlines the prognostic importance of ST2 measurement in patients ≥60 years of age with ischemic heart failure.CrossRef

85.

Lupon J, de Antonio M, Galan A, Vila J, Zamora E, Urrutia A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc Mayo Clin. 2013;88(3):234–43. doi:10.1016/j.mayocp.2012.09.016.CrossRef

86.

Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54(23):2174–9. doi:10.1016/j.jacc.2009.07.041.PubMedCrossRef

87.

Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD, et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers: Biochem Indic Expo, Response, Susceptibility Chem. 2013;18(3):250–6. doi:10.3109/1354750X.2013.773081.

88.

Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126(13):1596–604. doi:10.1161/CIRCULATIONAHA.112.129437.PubMedCrossRef

89.

Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem. 2013;59(3):536–46. doi:10.1373/clinchem.2012.191106.PubMedCrossRef

90.

AbouEzzeddine OF, Kane GC, Rodeheffer RJ, Chen HH, Saenger AK, Scott CG, et al. Abstract 17646: plasma levels of ST2 in the community: ST2 is associated with increased risk of incident heart failure and mortality but not with altered ventricular function. Circulation. 2012;126(21 Supplement):A17646.

91.

Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, Pascual-Figal DA, et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology. 2012;122(3):158–66. doi:10.1159/000338800.PubMedCrossRef

Title: The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers
Authors: George Karayannis
Filippos Triposkiadis
John Skoularigis
Panagiotis Georgoulias
Javed Butler
Gregory Giamouzis
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Heart Failure Reports / Issue 4/2013
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-013-0169-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Acute Heart Failure: Patient Characteristics and Pathophysiology

Heart Failure and Tachycardia-Induced Cardiomyopathy

Heart Failure in Children in Tropical Regions

Prognostic Factors in Patients Hospitalized for Heart Failure

Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction

Revascularization in Heart Failure in the Post-STICH Era

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials